Neurotech Pub Episode 9 – Building (and Funding) Neurotech Companies

The Drinks Bring Back All The Memories

Welcome to the Season 1 finale of Neurotech Pub. In this episode, Matt Angle speaks with fellow Neurotech CEOs, Konstantinos Alataris, Frank Fischer, and Marcus Gerhardt.

“We cover a lot in this discussion, but one of the big themes is how challenging it can be to raise money, to build neuro devices. This episode was originally recorded last winter, and it was instantly one of my favorite episodes. So like a fine wine, I laid it down until the time was right to share it with friends.

Since the episode was recorded, Nesos, Paradromics, and BlackRock all had major funding announcements. Nesos and BlackRock underwent rebranding campaigns, and NeuroPace went public on Nasdaq. This podcast was recorded during a bleak winter, but our optimism proved prescient. The podcast aged well, and now the field is the strongest, best funded, and most exciting that it’s ever been. I know you’ll enjoy the discussion.”
– Matt Angle, CEO, Paradromics

Click below to watch Episode 9. Listen wherever podcasts are found. Read the Annals of Neurotech Pub on Medium.

Guests: Konstantinos Alataris, Frank Fischer, and Marcus Gerhardt

1:04:50 | Investor Backing in Neurotech
1:10:55 | Brian Johnson’s Kernel
1:13:24 | Moderna Therapeutics

1:20:44 | BCI Future Is Underway
1:24:30 | RNS therapy for addictive behaviors
1:24:44 | Preclinical Research on Addictive Behavior
1:27:20 | Huma

// Director & Host: Matt Angle
// Producer: Lili Byrne and Ali Stuckey
// Editor: Jasper Sams
// Graphic Design: Midnight Measure Design